Marinus Pharma CS (MRNS)
DESCRIPTION:
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.
|
4.38 +0.10 (+2.34%) 07/03/19 [NASDAQ]
4.37 x 10 4.55 x 2
POST-MARKET 4.37 -0.01 (-0.23%) 15:32 ET
for Wed, Jul 3rd, 2019
|
||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
| Notes AA | ||||||||||||||||||||||||||||||||
| Notes AR | ||||||||||||||||||||||||||||||||
Reviews
There are no reviews yet.
Related products
Pharmaceutical & Health Watch
Cannabis Watch
Pharmaceutical & Health Watch
Cannabis Watch
Pharmaceutical & Health Watch
Be the first to review “Marinus Pharma CS (MRNS)”